Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer

M. Tamburini, C. Brambilla, L. Ferrari, T. Bombino, L. Gangeri, S. Rosso

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The psychometric characteristics of two indexes used to evaluate the subjective morbidity of chemotherapy regimens were analyzed. Both indexes assessed the duration of discomfort as perceived by the patient throughout therapy. The first index asked patients to state the number of days spent with 'discomfort', and the second index asked them which days they would like to eliminate altogether because of the unbearable symptoms experienced on those days. While the first index gives some idea of the duration of suffering, without defining it, the second highlights a specific time when the quality of her life was unacceptable to the patient. We studied these indexes in the form of a questionnaire completed by 168 women who had entered a cancer clinical trial. This trial evaluated the efficacy of primary chemotherapy in rendering conservative surgery feasible in women with operable breast cancer, but whose tumor size was greater than 3 cm. Four different treatment regimens were used: CMF, FAC, FEC, FNC (C = cyclophosphamide, M = methotrexate, F = fluorouracil, A = adriamycin, E = epirubicin, N = mitoxantrone). Seventy-nine patients were interviewed during chemotherapy and 89 during follow-up visits. Initial assessment of the reliability, discriminant and concurrent validity of the two indexes produced satisfactory results. Finally, we analyzed the responses given by 168 patients for a total of 600 treatment cycles. The average value of 'discomfort' was 3 days, whereas the average value of days 'to be eliminated' was 1. The range of subjective morbidity (for every cycle of treatment: 'discomfort' = 0-30 days; 'to be eliminated' = 0-20 days) was very broad. The two indexes were able to statistically differentiate among the drug regimens used for chemotherapy. CMF presented the highest subjective morbidity and FNC produced the lowest.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalAnnals of Oncology
Volume2
Issue number6
Publication statusPublished - 1991

Fingerprint

Chemotherapy
Quality of Life
Breast Cancer
Therapy
Breast Neoplasms
Drug Therapy
Evaluate
Morbidity
Therapeutics
Mitoxantrone
Epirubicin
Surgery
Tumors
Psychological Stress
Psychometrics
Methotrexate
Fluorouracil
Doxorubicin
Cyclophosphamide
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer. / Tamburini, M.; Brambilla, C.; Ferrari, L.; Bombino, T.; Gangeri, L.; Rosso, S.

In: Annals of Oncology, Vol. 2, No. 6, 1991, p. 417-422.

Research output: Contribution to journalArticle

@article{6a79444bb7b14f768916b0f431c99dbc,
title = "Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer",
abstract = "The psychometric characteristics of two indexes used to evaluate the subjective morbidity of chemotherapy regimens were analyzed. Both indexes assessed the duration of discomfort as perceived by the patient throughout therapy. The first index asked patients to state the number of days spent with 'discomfort', and the second index asked them which days they would like to eliminate altogether because of the unbearable symptoms experienced on those days. While the first index gives some idea of the duration of suffering, without defining it, the second highlights a specific time when the quality of her life was unacceptable to the patient. We studied these indexes in the form of a questionnaire completed by 168 women who had entered a cancer clinical trial. This trial evaluated the efficacy of primary chemotherapy in rendering conservative surgery feasible in women with operable breast cancer, but whose tumor size was greater than 3 cm. Four different treatment regimens were used: CMF, FAC, FEC, FNC (C = cyclophosphamide, M = methotrexate, F = fluorouracil, A = adriamycin, E = epirubicin, N = mitoxantrone). Seventy-nine patients were interviewed during chemotherapy and 89 during follow-up visits. Initial assessment of the reliability, discriminant and concurrent validity of the two indexes produced satisfactory results. Finally, we analyzed the responses given by 168 patients for a total of 600 treatment cycles. The average value of 'discomfort' was 3 days, whereas the average value of days 'to be eliminated' was 1. The range of subjective morbidity (for every cycle of treatment: 'discomfort' = 0-30 days; 'to be eliminated' = 0-20 days) was very broad. The two indexes were able to statistically differentiate among the drug regimens used for chemotherapy. CMF presented the highest subjective morbidity and FNC produced the lowest.",
author = "M. Tamburini and C. Brambilla and L. Ferrari and T. Bombino and L. Gangeri and S. Rosso",
year = "1991",
language = "English",
volume = "2",
pages = "417--422",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer

AU - Tamburini, M.

AU - Brambilla, C.

AU - Ferrari, L.

AU - Bombino, T.

AU - Gangeri, L.

AU - Rosso, S.

PY - 1991

Y1 - 1991

N2 - The psychometric characteristics of two indexes used to evaluate the subjective morbidity of chemotherapy regimens were analyzed. Both indexes assessed the duration of discomfort as perceived by the patient throughout therapy. The first index asked patients to state the number of days spent with 'discomfort', and the second index asked them which days they would like to eliminate altogether because of the unbearable symptoms experienced on those days. While the first index gives some idea of the duration of suffering, without defining it, the second highlights a specific time when the quality of her life was unacceptable to the patient. We studied these indexes in the form of a questionnaire completed by 168 women who had entered a cancer clinical trial. This trial evaluated the efficacy of primary chemotherapy in rendering conservative surgery feasible in women with operable breast cancer, but whose tumor size was greater than 3 cm. Four different treatment regimens were used: CMF, FAC, FEC, FNC (C = cyclophosphamide, M = methotrexate, F = fluorouracil, A = adriamycin, E = epirubicin, N = mitoxantrone). Seventy-nine patients were interviewed during chemotherapy and 89 during follow-up visits. Initial assessment of the reliability, discriminant and concurrent validity of the two indexes produced satisfactory results. Finally, we analyzed the responses given by 168 patients for a total of 600 treatment cycles. The average value of 'discomfort' was 3 days, whereas the average value of days 'to be eliminated' was 1. The range of subjective morbidity (for every cycle of treatment: 'discomfort' = 0-30 days; 'to be eliminated' = 0-20 days) was very broad. The two indexes were able to statistically differentiate among the drug regimens used for chemotherapy. CMF presented the highest subjective morbidity and FNC produced the lowest.

AB - The psychometric characteristics of two indexes used to evaluate the subjective morbidity of chemotherapy regimens were analyzed. Both indexes assessed the duration of discomfort as perceived by the patient throughout therapy. The first index asked patients to state the number of days spent with 'discomfort', and the second index asked them which days they would like to eliminate altogether because of the unbearable symptoms experienced on those days. While the first index gives some idea of the duration of suffering, without defining it, the second highlights a specific time when the quality of her life was unacceptable to the patient. We studied these indexes in the form of a questionnaire completed by 168 women who had entered a cancer clinical trial. This trial evaluated the efficacy of primary chemotherapy in rendering conservative surgery feasible in women with operable breast cancer, but whose tumor size was greater than 3 cm. Four different treatment regimens were used: CMF, FAC, FEC, FNC (C = cyclophosphamide, M = methotrexate, F = fluorouracil, A = adriamycin, E = epirubicin, N = mitoxantrone). Seventy-nine patients were interviewed during chemotherapy and 89 during follow-up visits. Initial assessment of the reliability, discriminant and concurrent validity of the two indexes produced satisfactory results. Finally, we analyzed the responses given by 168 patients for a total of 600 treatment cycles. The average value of 'discomfort' was 3 days, whereas the average value of days 'to be eliminated' was 1. The range of subjective morbidity (for every cycle of treatment: 'discomfort' = 0-30 days; 'to be eliminated' = 0-20 days) was very broad. The two indexes were able to statistically differentiate among the drug regimens used for chemotherapy. CMF presented the highest subjective morbidity and FNC produced the lowest.

UR - http://www.scopus.com/inward/record.url?scp=0025770550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025770550&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 417

EP - 422

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -